This is interesting. I’m sure I read it before but must have been daydreaming...

“Barring a significant scientific development that requires otherwise, studies conducted in accordance with the agreement [for Phase 3 trial] shall be presumed to be sufficient in objective and design for the purpose of obtaining marketing approval for the drug.”